MedTrace Logo

Pemetrexed/Cisplatin Intercalating Gefitinib Treating EGFR Wild NSCLC

NCT03374280 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 178

Last updated 2019-03-28

No results posted yet for this study

Summary

To investigate the curative effect between Pemetrexed/Cisplatin and Pemetrexed/Cisplatin intercalating Gefitinib Treating EGFR Wild NSCLC

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

pemetrexed/cisplatin intercalating gefitinib

DRUG

pemetrexed/cisplatin

Sponsors & Collaborators

  • Guangzhou Medical University

    lead OTHER

Principal Investigators

  • Jiajia Yu, MD · the ethics committee of the first affiliated hospital of Guangzhou MC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-01
Primary Completion
2019-12-30
Completion
2021-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03374280 on ClinicalTrials.gov